Top

Current Hepatology Reports

Published in:

01-12-2017 | Fatty Liver Disease (S Harrison and J George, Section Editors)

Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C

Authors: Takumi Kawaguchi, Hironori Koga, Takuji Torimura

Published in: Current Hepatology Reports | Issue 4/2017

Abstract

Purpose of Review

Patients with chronic hepatitis C infection frequently develop non-alcoholic fatty liver disease (NAFLD), which confers a risk of hepatocellular carcinoma (HCC). Although direct-acting antivirals allow the majority of patients to achieve a sustained virologic response (SVR), post-SVR patients still carry a non-negligible risk of HCC. This review summarizes recent findings regarding the pathogenesis of hepatitis C virus (HCV)-related NAFLD and its impact on post-SVR patients.

Recent Findings

The recently discovered HCV-induced steatosis mechanisms include the upregulation of microRNA-27 expression and the formation of HCV-lipoviral particles, which suppress β-oxidation and triglyceride hydrolysis, respectively. Recent studies also revealed the incidence of NAFLD even among post-SVR patients, as well as an association of steatosis with hepatic inflammation and hepatocarcinogenesis.

Summary

HCV induces changes in microRNA expression and lipoviral particles to directly promote the development of steatosis. In post-SVR patients, NAFLD is an important pathological condition related to hepatic inflammation and hepatocarcinogenesis.

Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637–48. https://doi.org/10.7326/M16-2575.PubMedCrossRef

Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49(3):739–44. https://doi.org/10.1002/hep.22703.PubMedCrossRef

Mahale P, Engels EA, Li R, et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2017; https://doi.org/10.1136/gutjnl-2017-313983.

Hengst J, Falk CS, Schlaphoff V, et al. Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis. 2016;214(12):1965–74. https://doi.org/10.1093/infdis/jiw457.PubMedCrossRef

Janjua NZ, Chong M, Kuo M, et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017;66(3):504–13. https://doi.org/10.1016/j.jhep.2016.10.028.PubMedCrossRef

Fukushima N, Kuromatsu R, Arinaga-Hino T, et al. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatol Res. 2010;40(9):911–22. https://doi.org/10.1111/j.1872-034X.2010.00699.x.PubMedCrossRef

Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017; https://doi.org/10.1016/j.jhep.2017.06.003.

VanWagner LB, Rinella ME. Extrahepatic manifestations of nonalcoholic fatty liver disease. Curr Hepatol Rep. 2016;15(2):75–85. https://doi.org/10.1007/s11901-016-0295-9.PubMedPubMedCentralCrossRef

Harrison SA. Steatosis and chronic hepatitis C infection: mechanisms and significance. Clin Gastroenterol Hepatol. 2005;3(10 Suppl 2):S92–6.PubMedCrossRef

10.

Ballestri S, Nascimbeni F, Romagnoli D, et al. Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis C virus infection—liver: the “musketeer” in the spotlight. Int J Mol Sci. 2016;17(3):355. https://doi.org/10.3390/ijms17030355.PubMedPubMedCentralCrossRef

11.

Castera L, Hezode C, Roudot-Thoraval F, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut. 2004;53(3):420–4.PubMedPubMedCentralCrossRef

12.

Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 2002;36(5):1266–72. https://doi.org/10.1053/jhep.2002.36370.PubMedCrossRef

13.

Harrison SA, Brunt EM, Qazi RA, et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2005;3(6):604–9.PubMedCrossRef

14.

Cheng FK, Torres DM, Harrison SA. Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy? J Viral Hepat. 2014;21(1):1–8. https://doi.org/10.1111/jvh.12172.PubMedCrossRef

15.

Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130(6):1636–42. https://doi.org/10.1053/j.gastro.2006.03.014.PubMedCrossRef

16.

Fartoux L, Chazouilleres O, Wendum D, et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology. 2005;41(1):82–7. https://doi.org/10.1002/hep.20519.PubMedCrossRef

17.

Kumar D, Farrell GC, Kench J, et al. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol. 2005;20(9):1395–400. https://doi.org/10.1111/j.1440-1746.2005.04007.x.PubMedCrossRef

18.

Lonardo A, Ballestri S, Guaraldi G, et al. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease—evidence from three different disease models: NAFLD. HCV and HIV World J Gastroenterol. 2016;22(44):9674–93. https://doi.org/10.3748/wjg.v22.i44.9674.PubMedCrossRef

19.

Goossens N, Negro F. Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infection. Rev Recent Clin Trials. 2014;9(3):204–9.PubMedCrossRef

20.

Hui JM, Kench J, Farrell GC, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol. 2002;17(8):873–81.PubMedCrossRef

21.

Islam MJ, Hikosaka K, Noritake H, et al. Pol I-transcribed hepatitis C virus genome RNA replicates, produces an infectious virus and leads to severe hepatic steatosis in transgenic mice. Biomed Res. 2015;36(3):159–67. https://doi.org/10.2220/biomedres.36.159.PubMedCrossRef

22.

Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126(3):840–8.PubMedCrossRef

23.

Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165(5):1499–508. https://doi.org/10.1016/S0002-9440(10)63408-6.PubMedPubMedCentralCrossRef

24.

Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2006;55(4):529–35. https://doi.org/10.1136/gut.2005.069674.PubMedPubMedCentralCrossRef

25.

Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570–6. https://doi.org/10.1111/j.1572-0241.2006.01038.x.PubMedCrossRef

26.

Hughes S, Samman S. The effect of zinc supplementation in humans on plasma lipids, antioxidant status and thrombogenesis. J Am Coll Nutr. 2006;25(4):285–91.PubMedCrossRef

27.

Himoto T, Nomura T, Tani J, et al. Exacerbation of insulin resistance and hepatic steatosis deriving from zinc deficiency in patients with HCV-related chronic liver disease. Biol Trace Elem Res. 2015;163(1–2):81–8. https://doi.org/10.1007/s12011-014-0177-3.PubMedCrossRef

28.

Vickers KC, Shoucri BM, Levin MG, et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology. 2013;57(2):533–42. https://doi.org/10.1002/hep.25846.PubMedCrossRef

29.

Murakami Y, Kawada N. MicroRNAs in hepatic pathophysiology. Hepatol Res. 2017;47(1):60–9. https://doi.org/10.1111/hepr.12730.PubMedCrossRef

30.

• Singaravelu R, Chen R, Lyn RK, et al. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatology. 2014;59(1):98–108. https://doi.org/10.1002/hep.26634. HCV induces miR-27, which causes hepatic steatosis through a decrease in β-oxidation. PubMedCrossRef

31.

Yamaguchi A, Tazuma S, Nishioka T, et al. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci. 2005;50(7):1361–71.PubMedCrossRef

32.

Garcia-Mediavilla MV, Pisonero-Vaquero S, Lima-Cabello E, et al. Liver X receptor alpha-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Lab Investig. 2012;92(8):1191–202. https://doi.org/10.1038/labinvest.2012.88.PubMedCrossRef

33.

• Bridge SH, Sheridan DA, Felmlee DJ, et al. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. J Hepatol. 2015;62(4):763–70. https://doi.org/10.1016/j.jhep.2014.11.016. Proprotein convertase subtilisin kexin type 9 and LDL concentrations were lower in HCV genotype 3 than genotype 1, indicating upregulation of LDL receptor activity is a unique feature of HCV genotype 3. PubMedCrossRef

34.

Romero-Gomez M, Rojas A. Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids. Hepatology. 2015;61(3):744–7. https://doi.org/10.1002/hep.27581.PubMedCrossRef

35.

Sun HY, Lin CC, Lee JC, et al. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. Gut. 2013;62(8):1193–203. https://doi.org/10.1136/gutjnl-2011-301798.PubMedCrossRef

36.

Harris C, Herker E, Farese RV Jr, et al. Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis. J Biol Chem. 2011;286(49):42615–25. https://doi.org/10.1074/jbc.M111.285148.PubMedPubMedCentralCrossRef

37.

• Ferguson D, Zhang J, Davis MA, et al. The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis. J Lipid Res. 2017;58(2):420–32. https://doi.org/10.1194/jlr.M073734. Perilipin 3, a lipid droplet scaffold protein, is required to develop hepatic steatosis in HCV core transgenic mice. PubMedCrossRef

38.

Katsume A, Tokunaga Y, Hirata Y, et al. A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes. Gastroenterology. 2013;145(4):865–73. https://doi.org/10.1053/j.gastro.2013.06.012.PubMedCrossRef

39.

Li JF, Qu F, Zheng SJ, et al. Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis. 2014;33(10):1725–32. https://doi.org/10.1007/s10096-014-2123-x.PubMedCrossRef

40.

Deevska GM, Rozenova KA, Giltiay NV, et al. Acid sphingomyelinase deficiency prevents diet-induced hepatic triacylglycerol accumulation and hyperglycemia in mice. J Biol Chem. 2009;284(13):8359–68. https://doi.org/10.1074/jbc.M807800200.PubMedPubMedCentralCrossRef

41.

Chang ML, Yeh HC, Tsou YK, et al. HCV core-induced nonobese hepatic steatosis is associated with hypoadiponectinemia and is ameliorated by adiponectin administration. Obesity (Silver Spring). 2012;20(7):1474–80. https://doi.org/10.1038/oby.2012.45.CrossRef

42.

Korah TE, El-Sayed S, Elshafie MK, et al. Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis. World J Hepatol. 2013;5(2):74–81. https://doi.org/10.4254/wjh.v5.i2.74.PubMedPubMedCentralCrossRef

43.

Rusu E, Jinga M, Enache G, et al. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C—a randomized trial. Nutr J. 2013;12:119. https://doi.org/10.1186/1475–2891–12-119.PubMedPubMedCentralCrossRef

44.

Stattermayer AF, Rutter K, Beinhardt S, et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol. 2012;57(3):492–8. https://doi.org/10.1016/j.jhep.2012.04.036.PubMedCrossRef

45.

Yasui K, Kawaguchi T, Shima T, et al. Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C. J Gastroenterol. 2015;50(8):887–93. https://doi.org/10.1007/s00535-014-1018-z.PubMedCrossRef

46.

Clark PJ, Thompson AJ, Zhu Q, et al. The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci. 2012;57(8):2213–21. https://doi.org/10.1007/s10620-012-2171-y.PubMedPubMedCentralCrossRef

47.

Trepo E, Pradat P, Potthoff A, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology. 2011;54(1):60–9. https://doi.org/10.1002/hep.24350.PubMedCrossRef

48.

Miyaaki H, Miuma S, Taura N, et al. PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C. Hepatol Res. 2017; https://doi.org/10.1111/hepr.12920.

49.

•• Fan JH, Xiang MQ, Li QL, et al. PNPLA3 rs738409 polymorphism associated with hepatic steatosis and advanced fibrosis in patients with chronic hepatitis C virus: a meta-analysis. Gut Liver. 2016;10(3):456–63. https://doi.org/10.5009/gnl15261. The impact of the PNPLA3 polymorphism on steatosis is notable in Caucasians. PubMedCrossRef

50.

•• Petta S, Vanni E, Bugianesi E, et al. PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. Aliment Pharmacol Ther. 2015;41(10):939–48. https://doi.org/10.1111/apt.13169. In n434 non-obese patients, the PNPLA3 polymorphism is associated with steatohepatitis. PubMedCrossRef

51.

Ampuero J, Del Campo JA, Rojas L, et al. PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. Ann Hepatol. 2014;13(4):356–63.PubMed

52.

Zampino R, Coppola N, Cirillo G, et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat. 2013;20(8):517–23. https://doi.org/10.1111/jvh.12053.PubMedCrossRef

53.

Scheiner B, Mandorfer M, Schwabl P, et al. The impact of PNPLA3 rs738409 SNP on liver fibrosis progression, portal hypertension and hepatic steatosis in HIV/HCV coinfection. PLoS One. 2015;10(11):e0143429. https://doi.org/10.1371/journal.pone.0143429.PubMedPubMedCentralCrossRef

54.

Nakamura M, Kanda T, Nakamoto S, et al. No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV. PLoS One. 2013;8(12):e81312. https://doi.org/10.1371/journal.pone.0081312.PubMedPubMedCentralCrossRef

55.

Coppola N, Rosa Z, Cirillo G, et al. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. Liver Int. 2015;35(8):1959–63. https://doi.org/10.1111/liv.12781.PubMedCrossRef

56.

Milano M, Aghemo A, Mancina RM, et al. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology. 2015;62(1):111–7. https://doi.org/10.1002/hep.27811.PubMedCrossRef

57.

•• Eslam M, Mangia A, Berg T, et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology. 2016;64(1):34–46. https://doi.org/10.1002/hep.28475. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C. PubMedCrossRef

58.

Sagnelli C, Merli M, Uberti-Foppa C, et al. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. World J Gastroenterol. 2016;22(38):8509–18. https://doi.org/10.3748/wjg.v22.i38.8509.PubMedPubMedCentralCrossRef

59.

Petta S, Maida M, Grimaudo S, et al. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. Liver Int. 2016;36(2):198–204. https://doi.org/10.1111/liv.12918.PubMedCrossRef

60.

Tillmann HL, Patel K, Muir AJ, et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol. 2011;55(6):1195–200. https://doi.org/10.1016/j.jhep.2011.03.015.PubMedPubMedCentralCrossRef

61.

Valenti L, Aghemo A, Stattermayer AF. Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. J Hepatol. 2012;56(5):1209–1210; author reply 10-2. https://doi.org/10.1016/j.jhep.2011.10.024.PubMedCrossRef

62.

Taliani G, Spaziante M, Biliotti E, et al. IL28B gene polymorphisms and US liver fatty changes in patients who spontaneously cleared hepatitis C virus infection. PLoS One. 2013;8(8):e67301. https://doi.org/10.1371/journal.pone.0067301.PubMedPubMedCentralCrossRef

63.

Sato M, Kondo M, Tateishi R, et al. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One. 2014;9(3):e91822. https://doi.org/10.1371/journal.pone.0091822.PubMedPubMedCentralCrossRef

64.

Ohnishi M, Tsuge M, Kohno T, et al. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol. 2012;47(7):834–44. https://doi.org/10.1007/s00535-012-0550-y.PubMedCrossRef

65.

Zampino R, Ingrosso D, Durante-Mangoni E, et al. Microsomal triglyceride transfer protein (MTP)-493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J Viral Hepat. 2008;15(10):740–6. https://doi.org/10.1111/j.1365-2893.2008.00994.x.PubMedCrossRef

66.

Magri MC, Prata TV, Manchiero C, et al. Genetic variation in the microsomal triglyceride transfer protein (−493G/T) is associated with hepatic steatosis in patients infected with hepatitis C virus. BMC Infect Dis. 2017;17(1):235. https://doi.org/10.1186/s12879-017-2340-x.PubMedPubMedCentralCrossRef

67.

Mirandola S, Osterreicher CH, Marcolongo M, et al. Microsomal triglyceride transfer protein polymorphism (−493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C. Liver Int. 2009;29(4):557–65. https://doi.org/10.1111/j.1478-3231.2008.01892.x.PubMedCrossRef

68.

Petit JM, Masson D, Minello A, et al. Lack of association between microsomal triglyceride transfer protein gene polymorphism and liver steatosis in HCV-infected patients. Mol Genet Metab. 2006;88(2):196–8. https://doi.org/10.1016/j.ymgme.2005.12.006.PubMedCrossRef

69.

Siqueira ER, Oliveira CP, Correa-Giannella ML, et al. MTP-493G/T gene polymorphism is associated with steatosis in hepatitis C-infected patients. Braz J Med Biol Res. 2012;45(1):72–7.PubMedCrossRef

70.

Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–5. https://doi.org/10.1038/ng.257.PubMedPubMedCentralCrossRef

71.

Kawaguchi T, Sumida Y, Umemura A, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One. 2012;7(6):e38322. https://doi.org/10.1371/journal.pone.0038322.PubMedPubMedCentralCrossRef

72.

Huang CF, Chen JJ, Yeh ML, et al. PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. Sci Rep. 2015;5:11901. https://doi.org/10.1038/srep11901.PubMedPubMedCentralCrossRef

73.

Cai T, Dufour JF, Muellhaupt B, et al. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol. 2011;55(3):529–35. https://doi.org/10.1016/j.jhep.2010.12.020.PubMedCrossRef

74.

Valenti L, Rumi M, Galmozzi E, et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology. 2011;53(3):791–9. https://doi.org/10.1002/hep.24123.PubMedCrossRef

75.

O’Hare EA, Yang R, Yerges-Armstrong LM, et al. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine. Hepatology. 2017;65(5):1526–42. https://doi.org/10.1002/hep.29021.PubMedCrossRef

76.

Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet. 2014;46(4):345–51. https://doi.org/10.1038/ng.2926.PubMedPubMedCentralCrossRef

77.

Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9. https://doi.org/10.1038/ng.449.PubMedCrossRef

78.

Petta S, Rosso C, Leung R, et al. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clin Gastroenterol Hepatol. 2013;11(3):311–317 e1. https://doi.org/10.1016/j.cgh.2012.11.022.PubMedCrossRef

79.

D’Ambrosio R, Aghemo A, De Francesco R, et al. The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. Int J Mol Sci. 2014;15(5):7213–24. https://doi.org/10.3390/ijms15057213.PubMedPubMedCentralCrossRef

80.

Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. World J Gastroenterol. 2010;16(16):1943–52.PubMedPubMedCentralCrossRef

81.

Kawaguchi T, Taniguchi E, Itou M, et al. The pathogenesis, complications and therapeutic strategy for hepatitis C virus-associated insulin resistance in the era of anti-viral treatment. Rev Recent Clin Trials. 2010;5(3):147–57.PubMedCrossRef

82.

Chehadeh W, Al-Nakib W. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy. J Med Virol. 2009;81(4):610–8. https://doi.org/10.1002/jmv.21396.PubMedCrossRef

83.

Pandya P, Pant C, Taylor R, et al. Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome. J Investig Med. 2017;65(4):765–71. https://doi.org/10.1136/jim-2016-000343.PubMedCrossRef

84.

Hum J, Jou JH, Green PK, et al. Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus. Diabetes Care. 2017; https://doi.org/10.2337/dc17-0485.

85.

Morales AL, Junga Z, Singla MB, et al. Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. World J Hepatol. 2016;8(35):1557–63. https://doi.org/10.4254/wjh.v8.i35.1557.PubMedPubMedCentralCrossRef

86.

•• Hashimoto S, Yatsuhashi H, Abiru S, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment. PLoS One. 2016;11(9):e0163644. https://doi.org/10.1371/journal.pone.0163644. An increase in serum LDL cholesterol level is seen in post-SVR patients by DAAs treatment. PubMedPubMedCentralCrossRef

87.

Mauss S, Berger F, Wehmeyer MH, et al. Effect of antiviral therapy for HCV on lipid levels. Antivir Ther. 2017;21(1):81–8. https://doi.org/10.3851/IMP3094.PubMed

88.

Juanbeltz R, Goni Esarte S, Uriz-Otano JI, et al. Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgrad Med. 2017;129(4):476–83. https://doi.org/10.1080/00325481.2017.1311197.PubMedCrossRef

89.

Bassendine MF, Nielsen SU, Bridge SH, et al. Hepatitis C virus and atherosclerosis: a legacy after virologic cure? Clin Res Hepatol Gastroenterol. 2017;41(1):25–30. https://doi.org/10.1016/j.clinre.2016.09.008.PubMedCrossRef

90.

Younossi ZM, Stepanova M, Estep M, et al. Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. J Hepatol. 2016;64(1):29–36. https://doi.org/10.1016/j.jhep.2015.08.027.PubMedCrossRef

91.

Miyajima I, Kawaguchi T, Fukami A, et al. Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: a population-based study in an HCV hyperendemic area. J Gastroenterol. 2013;48(1):93–100. https://doi.org/10.1007/s00535-012-0610-3.PubMedCrossRef

92.

Sun HY, Cheng PN, Tseng CY, et al. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection. Gut. 2017; https://doi.org/10.1136/gutjnl-2017-313832.

93.

Liang CC, Liu CH, Chung CS, et al. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy. J Infect Dis. 2015;211(9):1429–36. https://doi.org/10.1093/infdis/jiu630.PubMedCrossRef

94.

• Welsch C, Efinger M, von Wagner M, et al. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response. PLoS One. 2017;12(2):e0171755. https://doi.org/10.1371/journal.pone.0171755. In 834 post-SVR patients, NAFLD was a strong predictor for post-SVR ALT elevation. PubMedPubMedCentralCrossRef

95.

Saito M, Seo Y, Yano Y, et al. Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review. Clin J Gastroenterol. 2012;5(2):119–26. https://doi.org/10.1007/s12328-012-0284-7.PubMedCrossRef

96.

El-Serag HB, Kanwal F, Richardson P, et al. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology. 2016;64(1):130–7. https://doi.org/10.1002/hep.28535.PubMedPubMedCentralCrossRef

97.

Tanaka A, Uegaki S, Kurihara H, et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol. 2007;13(39):5180–7.PubMedPubMedCentralCrossRef

98.

•• Nirei K, Matsumura H, Kumakawa M, et al. Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. Int J Med Sci. 2017;14(1):45–52. https://doi.org/10.7150/ijms.17202. In 282 post-SVR patients, steatosis was identified as an independent risk factor for the development of HCC. PubMedPubMedCentralCrossRef

99.

Hung CH, Kuo FY, Wang JH, et al. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Antivir Ther. 2006;11(4):483–9.PubMed

Title: Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C
Authors: Takumi Kawaguchi
Hironori Koga
Takuji Torimura
Publication date: 01-12-2017
Publisher: Springer US
Published in: Current Hepatology Reports / Issue 4/2017
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-017-0370-x

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2017

Hepatotoxicity of New Antitumor Agents

Overview of Clinical Treatment Trials for NASH

Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD

Genetic and Epigenetic Associations of NAFLD: Focus on Clinical Decision Making

Autoimmune Hepatitis-Induced by Drugs: a Challenging Diagnosis

The Management of Bleeding from Anorectal Varices

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page